1. Scrip
  2. >>New Products

Lynparza Gets US OK For Pancreatic Cancer

FDA Says Yes To Third Cancer Type

 
• By Alexandra Shimmings

The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.

ApproveOnKeyboard_1200x675
• Source: Shutterstock

The US Food and Drug Administration has approved AstraZeneca PLC and Merck & Co. Inc.’s Lynparza for use in a third tumor type, pancreatic cancer, less than two weeks after its advisory panel gave a narrow nod to the new indication.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.